Evidence map›Paper›PMID 41303456›Full record

ArticleInternational journal of molecular sciences2025

Extracellular ATP Suppresses Perlecan Core Protein Synthesis via P2Y2 Receptor-Mediated Inhibition of Akt Signaling in Cultured Vascular Endothelial Cells.

Lihito Ikeuchi, Takato Hara, Kazuki Kitabatake, Fumiaki Uchiumi, Chika Yamamoto, Mitsutoshi Tsukimoto, Tomoya Fujie, Toshiyuki Kaji

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lihito IkeuchiLaboratory of Environmental Health, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika 125-8585, Japan.
Takato HaraDepartment of Environmental Health, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi 274-8510, Japan.ORCID 0009-0005-0013-7917
Kazuki KitabatakeDepartment of Radiation Biosciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika 125-8585, Japan.
Fumiaki UchiumiDepartment of Gene Regulation, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika 125-8585, Japan.ORCID 0000-0002-5759-4829
Chika YamamotoDepartment of Environmental Health, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi 274-8510, Japan.
Mitsutoshi TsukimotoDepartment of Radiation Biosciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika 125-8585, Japan.
Tomoya FujieLaboratory of Environmental Health, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika 125-8585, Japan.ORCID 0000-0002-5793-9401
Toshiyuki KajiLaboratory of Environmental Health, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika 125-8585, Japan.ORCID 0000-0002-7393-2656

Funding

the Japan Society for the Promotion of Science KAKENHI JP23K16312the Japan Society for the Promotion of Science KAKENHI JP25K15460
6 · The paper itself

Abstract

Perlecan, a major heparan sulfate proteoglycan in the vascular basement membrane, plays an essential role in maintaining endothelial barrier integrity, regulating fibroblast growth factor-2 signaling, and exerting anticoagulant activity. Although alterations in perlecan expression are implicated in the initiation and progression of atherosclerosis, the upstream regulatory mechanisms remain unclear. In this study, we investigated the effects of extracellular ATP on perlecan expression in vascular endothelial cells. ATP, but not ADP or adenosine, suppressed perlecan expression at both mRNA and protein levels in a time- and concentration-dependent manner. This suppression was recovered by knockdown of P2Y2 receptor (P2Y2R), but not by P2X4 receptor, P2X7 receptor, or P2Y1 receptor knockdown, indicating the selective involvement of P2Y2R. Mechanistically, ATP reduced Akt phosphorylation mediated by P2Y2R, and inhibition of Akt by inhibitors decreased perlecan expression, whereas inhibitors of phosphoinositide 3-kinase, mammalian target of rapamycin complex 1, extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, c-Jun N-terminal kinases did not exhibit this recovery effect. These results suggest that ATP downregulates perlecan synthesis via the P2Y2R-mediated inhibition of Akt signaling. Given that ATP is markedly elevated under pathological conditions, such as inflammation and platelet activation, suppression of perlecan synthesis is an important mechanism by which ATP promotes vascular disease progression.

Indexed as

Adenosine TriphosphateEndothelial CellsHeparan Sulfate ProteoglycansProtein BiosynthesisProto-Oncogene Proteins c-aktReceptors, Purinergic P2Y2Signal TransductionCells, CulturedHumansHuman Umbilical Vein Endothelial CellsPhosphorylationAdenosine TriphosphateHeparan Sulfate ProteoglycansperlecanProto-Oncogene Proteins c-aktReceptors, Purinergic P2Y2ATPheparan sulfate proteoglycanperlecanpurinergic receptorvascular endothelial cell

Identifiers

PMID41303456
PMCPMC12652865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.